Dave sits down with nurse practitioner and former Retatrutide clinical trial participant David White to break down the biggest obesity headlines from the 2026 American Diabetes Association Conference. Together, they explore the latest data on Retatrutide&#x27;s potential to deliver bariatric surgery-level weight loss, improve cardiometabolic health, and reshape the future of obesity and type 2 diabetes treatment.<br><br>otplinks.com

Retatrutide Just Reached Bariatric Surgery Results

On The Pen GLP-1 News

Last week was the American Diabetes Association Conference and so much news came out of that event. But the main headline leaving that massive conference was really the topic of Retatrutide, a topic that we've discussed for the last three and a half years here at On The Pen. And really, we are right around the corner from approval, which means we are at that time where we're getting so much data

to try to process as patients living with the disease of obesity. Is this the next thing that you will be on and why? And in order to really unpack this conversation, I thought it was best to talk to somebody who really understands the science. And so I invited a longtime acquaintance through Twitter and follower of On The Pen. David White is a nurse practitioner out of the state of Michigan and self-proclaimed Retatrutide,

glucagon nerd, and he is deep in the data on this stuff and was present at ADA to learn all about all things Retatrutide. So we're going to invite David White into On The Pen to discuss this year's ADA conference. David, welcome to On The Pen. Hey, thanks for having me. Yeah, super exciting to have you here.

I have followed you pretty closely over the last couple of years, and really, we've kind of gone back and forth over time to find the right time to have you on the program. And I can think of no better time than now. David, why don't you give everybody a little bit of a background about yourself, who you are, what you do, and how you became the sort of go-to source on Retatrutide information on Twitter? Sure. So, like you said, I'm a nurse practitioner.

Retatrutide Just Reached Bariatric Surgery Results

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Retatrutide Just Reached Bariatric Surgery Results

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.